AstraZeneca's SEC report reveals the discontinuation of the CAPItello-280 trial for mCRPC. Discover the reasons, trial details, and future strategies in prostate cancer treatment.
Explore MEI Pharma, Inc.'s Q4 2024 financial report, highlighting key insights, operational hurdles, and future growth potential. A thorough analysis for investors eyeing MEIP.
Explore Anixa Biosciences, Inc.'s financial performance, clinical trial updates, and stock outlook. Key insights reveal challenges in revenue and rising losses while maintaining a hold recommendation.
Explore Affimed N.V.'s latest 6-K filing detailing significant clinical trial updates for AFM24, safety profile, efficacy results, and a robust cash position projected into 2025.